Gene Remedy-Targeted Bluebird Bio Receives Rival Takeover Provide, Inventory Jumps – bluebird bio (NASDAQ:BLUE)

Bluebird Bio, Inc. BLUE acquired an unsolicited, non-binding written proposal from Ayrmid Ltd. on Friday.

Ayrmid has proposed to accumulate Bluebird for an upfront money fee of $4.50 per share and a one-time contingent worth proper of $6.84 per share payable upon attaining a web gross sales milestone.

In February 2025, Bluebird entered right into a definitive settlement with Carlyle and SK Capital Companions to be acquired and brought non-public for $3.00 per share in money and a one-time contingent worth proper of $6.84 per share payable upon achievement of a web gross sales milestone.

Additionally Learn: FDA-Authorised Sickle Cell Therapies From Bluebird Bio And Vertex Be part of Medicaid Innovation Program

Bluebird beforehand engaged in discussions with Ayrmid as a part of its complete evaluation of strategic options.

Ayrmid didn’t submit any proposal to Bluebird throughout that course of.

Per its fiduciary duties, the Bluebird Board of Administrators is reviewing the Ayrmid Proposal in session with its authorized and monetary advisors.

In November 2024, the FDA raised considerations about life-threatening hematologic malignancies in sufferers handled with Bluebird Bio’s Skysona (elivaldogene autotemcel), a gene remedy for early, energetic cerebral adrenoleukodystrophy (CALD).

The company has acquired stories of myelodysplastic syndrome and acute myeloid leukemia linked to Skysona, with circumstances rising 14 to 92 months post-treatment throughout scientific trials.

Worth Motion: BLUE inventory is up 7.84% at $4.40 on the final verify Monday.

Learn Subsequent:

Picture: Shutterstock